This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Diffusion Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Diffusion Pharmaceuticals.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02

Aug 12

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Feb 25

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Nov 12

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Jun 25

Diffusion Pharmaceuticals EPS misses by $0.02

May 10

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Mar 08

Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Nov 23

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Diffusion Pharmaceuticals no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:DFFN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2023	N/A	-13	-14	-14	N/A
3/31/2023	N/A	-15	-15	-15	N/A
12/31/2022	N/A	-16	-15	-15	N/A
9/30/2022	N/A	-15	-15	-15	N/A
6/30/2022	N/A	-24	-15	-15	N/A
3/31/2022	N/A	-24	-14	-14	N/A
12/31/2021	N/A	-24	-15	-15	N/A
9/30/2021	N/A	-25	-15	-15	N/A
6/30/2021	N/A	-17	-15	-15	N/A
3/31/2021	N/A	-18	-15	-15	N/A
12/31/2020	N/A	-16	-14	-14	N/A
9/30/2020	N/A	-16	-13	-13	N/A
6/30/2020	N/A	-14	-11	-11	N/A
3/31/2020	N/A	-12	-11	-11	N/A
12/31/2019	N/A	-12	-10	-10	N/A
9/30/2019	N/A	-14	-10	-10	N/A
6/30/2019	N/A	-18	-10	-10	N/A
3/31/2019	N/A	-18	-10	-10	N/A
12/31/2018	N/A	-27	-11	-11	N/A
9/30/2018	N/A	-20	-10	-10	N/A
6/30/2018	N/A	-10	-12	-12	N/A
3/31/2018	N/A	4	-13	-12	N/A
12/31/2017	N/A	-3	-13	-12	N/A
9/30/2017	N/A	-7	-12	-11	N/A
6/30/2017	N/A	-15	-10	-9	N/A
3/31/2017	N/A	-30	N/A	-10	N/A
12/31/2016	N/A	-18	N/A	-11	N/A
9/30/2016	N/A	-18	N/A	-12	N/A
6/30/2016	N/A	-14	N/A	-11	N/A
3/31/2016	N/A	-12	N/A	-9	N/A
12/31/2015	N/A	-7	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if DFFN's forecast earnings growth is above the savings rate (2.2%).

Beneficios vs. Mercado: Insufficient data to determine if DFFN's earnings are forecast to grow faster than the US market

Beneficios de alto crecimiento: Insufficient data to determine if DFFN's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if DFFN's revenue is forecast to grow faster than the US market.

Ingresos de alto crecimiento: Insufficient data to determine if DFFN's revenue is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if DFFN's Return on Equity is forecast to be high in 3 years time

This company is no longer active

Diffusion Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to US$100.00

Price target lowered to US$2.00

Recent updates

EIP Pharma, Inc. completed the acquisition of Diffusion Pharmaceuticals Inc. (NasdaqCM:DFFN) in a reverse merger transaction.

Diffusion Pharmaceuticals Inc. Announces Resignation of William K. Hornung as CFO

Diffusion Pharmaceuticals Inc. Announces Resignation of Christopher D. Galloway as Chief Medical Officer, Effective March 1, 2023

High number of new and inexperienced directors

LifeSci Special Opportunities Master Fund Ltd Issues an Open Letter to Shareholders of Diffusion Pharmaceuticals Inc

High number of new and inexperienced directors

Diffusion Pharmaceuticals Inc. Announces Resignation of Eric Francois from the Board of Directors and All Committees and Subcommittees

Diffusion Pharmaceuticals Inc., Annual General Meeting, Dec 30, 2022

Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger as Chief Regulatory Officer

Diffusion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$100.00

High number of new and inexperienced directors

Diffusion Pharmaceuticals Announces 1-For-50 Reverse Stock Split as Part of Nasdaq Compliance Plan

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

High number of new and inexperienced directors

High number of new and inexperienced directors

Diffusion Pharmaceuticals Inc. Announces Board Appointments

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial

Diffusion Pharmaceuticals Inc. Doses First Participants in Altitude Trial

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Diffusion Pharmaceuticals Inc. Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division

Co-Founder & Director John Gainer has left the company

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Diffusion Pharmaceuticals Inc. Reports Final Results from Its Phase 1B Study of Trans Sodium Crocetinate in Hospitalized Covid-19 Patients

Diffusion Pharmaceuticals EPS misses by $0.02

Diffusion Pharmaceuticals Doses First Participants in TCOM Study

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

New 90-day high: US$1.49

New 90-day high: US$1.04

Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Price target lowered to US$2.00

New 90-day low: US$0.75

Diffusion Pharmaceuticals Inc. Appoints Christopher D. Galloway as Chief Medical Officer

Diffusion Pharmaceuticals Appoints William Elder as General Counsel and Corporate Secretary

Diffusion Pharmaceuticals Names Dr. Robert Cobuzzi as Chief Executive Officer

New 90-day low - US$0.78

New 90-day high - US$1.47

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento